NRG Oncology Trial Shows Clinical Improvements for Intermediate-Risk Prostate Cancer Men

NRG Oncology Trial Shows Clinical Improvements for Intermediate-Risk Prostate Cancer Men

Results from the phase 3 NRG Oncology RTOG 0815 clinical study comparing dose-escalated radiotherapy (RT) alone to dose-escalated RT with short-term